I don't think many would be overly happy with Harvest's...

I don't think many would be overly happy with Harvest's performance since they gor their licence. I don't think it's unrealistic to believe that we could have been sitting closer to $1B valuation had plans been executed on time and delivered.
The biggest sticking point for me is that after all the plan changing we seem to have gone back to the original idea of expanding Duncan, only now years have passed. Can't get that time back to catch up. Massive bungle in getting up to a decent capacity.
On the flipside happy to see Satipharm & Dreamwater gaining traction, those are nice figures being mentioned but need to see it in the financials.